Journal Report

Investigational New Drugs

Download PDF
Journal Information
Journal Title
Investigational New Drugs
Publisher
Springer
ISSN
0167-6997
E-ISSN
1573-0646
Database
SCOPUS
Domain
Health Sciences, Life Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials
Yue Yuan, Hongkai Yan, Qinhang Wu
2026-10-8
DOI: 10.1007/s10637-026-01635-x
Parthenolide enhances imatinib activity in gastrointestinal stromal tumor models through stress-associated apoptosis
Chuang-Ming Zheng, Longyi Piao, Zhenggen Piao et al.
2026-9-15
DOI: 10.1007/s10637-026-01631-1
First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors
Rachel Galot, Zahra Castel-Ajgal, Nuria Kotecki et al.
2026-9-14
DOI: 10.1007/s10637-026-01636-w
Qishen Yiqi Dripping Pills ameliorate doxorubicin-induced cardiotoxicity: a study based on bioinformatics and experimental verification
Jiangtao Wang, Jian Yu, Dong Cao et al.
2026-8-28
DOI: 10.1007/s10637-026-01634-y
Influence of LGALS3 polymorphisms on chemotherapy-induced peripheral neuropathy in patients with metastatic pancreatic cancer treated with gemcitabine and nab-paclitaxel: an exploratory biomarker analysis of the GENESECT study
Masahiro Hatori, Daiki Tsuji, Kyoka Nagai et al.
2026-8-28
DOI: 10.1007/s10637-026-01632-0
Inhibition of SHP2 enhances the effects of selective receptor tyrosine kinase inhibitors in untreated preclinical models of RET-mutated thyroid cancer
Wenjun Xie, Mengrang Tian, Weike Ma et al.
2026-8-27
DOI: 10.1007/s10637-026-01633-z
Novel EGFR tyrosine kinase inhibitors exhibiting intrinsic fluorescence
Amelia Kierasińska-Kałka, Adrianna Rutkowska, Jacek Mularski et al.
2026-7-23
DOI: 10.1007/s10637-026-01625-z
The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells
Yunlong Pei, Jiaxun Wang, Taylor Smith et al.
2026-7-17
DOI: 10.1007/s10637-026-01629-9
Characterizing the post-market safety profile of lazertinib: a pharmacovigilance study of the FDA Adverse Events Reporting System Database
Connor Frey
2026-7-10
DOI: 10.1007/s10637-026-01630-2
A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors
Daruka Mahadevan, Jay Parekh, Joseph T. Beck et al.
2026-7-7
DOI: 10.1007/s10637-026-01626-y
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 3, 2026 02:48